Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash-to-Debt No Debt
AVXS's Cash-to-Debt is ranked higher than
64% of the 943 Companies
in the Global Biotechnology industry.

( Industry Median: 54.02 vs. AVXS: No Debt )
Ranked among companies with meaningful Cash-to-Debt only.
AVXS' s Cash-to-Debt Range Over the Past 10 Years
Min: N/A  Med: No Debt Max: No Debt
Current: No Debt
N/A
No Debt
Interest Coverage No Debt
AVXS's Interest Coverage is ranked lower than
99.99% of the 453 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. AVXS: No Debt )
Ranked among companies with meaningful Interest Coverage only.
AVXS' s Interest Coverage Range Over the Past 10 Years
Min: No Debt  Med: No Debt Max: No Debt
Current: No Debt
Altman Z-Score: 44.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE % -45.23
AVXS's ROE % is ranked lower than
59% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: -36.35 vs. AVXS: -45.23 )
Ranked among companies with meaningful ROE % only.
AVXS' s ROE % Range Over the Past 10 Years
Min: -140.56  Med: -97.65 Max: -45.23
Current: -45.23
-140.56
-45.23
ROA % -41.70
AVXS's ROA % is ranked lower than
62% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: -29.87 vs. AVXS: -41.70 )
Ranked among companies with meaningful ROA % only.
AVXS' s ROA % Range Over the Past 10 Years
Min: -807.09  Med: -243.88 Max: -41.7
Current: -41.7
-807.09
-41.7
ROC (Joel Greenblatt) % -519.90
AVXS's ROC (Joel Greenblatt) % is ranked lower than
59% of the 907 Companies
in the Global Biotechnology industry.

( Industry Median: -394.49 vs. AVXS: -519.90 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
AVXS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -109850  Med: -66010.99 Max: -519.9
Current: -519.9
-109850
-519.9
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» AVXS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-11 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

AVXS Guru Trades in Q2 2016

Jim Simons 5,831 sh (New)
Paul Tudor Jones Sold Out
» More
Q3 2016

AVXS Guru Trades in Q3 2016

Paul Tudor Jones 13,500 sh (New)
Jim Simons 53,900 sh (+824.37%)
» More
Q4 2016

AVXS Guru Trades in Q4 2016

Steven Cohen 540,400 sh (New)
Paul Tudor Jones Sold Out
Jim Simons 42,300 sh (-21.52%)
» More
Q1 2017

AVXS Guru Trades in Q1 2017

Andreas Halvorsen 381,626 sh (New)
Steven Cohen 717,514 sh (+32.77%)
Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with AVXS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325412    SIC: 2834
Compare:NAS:SRPT, NAS:FGEN, OTCPK:MPSYY, NAS:TBPH, NAS:DBVT, NYSE:CBM, OTCPK:BVNRY, NAS:HALO, NAS:ONCE, NAS:AAAP, NAS:PRTA, NAS:PTLA, NAS:BPMC, NAS:LXRX, NAS:BGNE, NYSE:AXON, NAS:CLVS, NAS:ARRY, NAS:AGIO, NAS:PBYI » details
Traded in other countries:AX4.Germany,
Headquarter Location:USA
AveXis Inc is a clinical-stage gene therapy company. It is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate is AVXS-101.

AveXis Inc was formed on March 8, 2010 in the state of Delaware as BioLife Cell Bank, LLC. In January 2012, the Company converted from a limited liability company to a corporation, BioLife Cell Bank, Inc. In January 2014, the Company amended and restated its Certificate of Incorporation to change its name to AveXis, Inc. It is a clinical-stage gene therapy company. The Company is engaged in developing and commercializing novel treatments for patients suffering from rare and life-threatening neurological genetic diseases. Its product candidate, AVXS-101, is a gene therapy product candidate currently in a Phase 1 clinical trial for the treatment of spinal muscular atrophy, or SMA, Type 1, the genetic cause of infant mortality. The Company manages its operations as a single segment, which is developing and commercializing gene therapy treatments for patients suffering from rare and life-threatening neurological genetic diseases. The Company competes with pharmaceutical and biotechnology companies, academic research institutions, government agencies and public and private research institutions.

Top Ranked Articles about AveXis Inc

AveXis Reports First Quarter 2017 Financial and Operating Results
AveXis to Report First Quarter 2017 Financial and Operating Results
AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the American Academy of Neurology
AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Meeting of the American Academy of Neurology
AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 Financial and Operating Results on March 16, 2017

-- Conference call and webcast on March 16 at 4:30 p.m. EDT --
CHICAGO, March 09, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, will announce topline results from the Phase 1 clinical trial of AVXS-101 in patients with SMA Type 1, and financial and operating results for the fourth quarter and full year ended December 31, 2016 on Thursday, March 16, 2017 after the close of U.S.-based financial markets. AveXis management will host a conference call and live webcast at 4:30 p.m. Eastern Daylight Time. Analysts and investors can participate in the conference call by dialing (844) 889-6863 for domestic callers and (661) 378-9762 for international callers, using the conference ID 84652584. The webcast can be accessed live on the Events and Presentations page in the Investors and Media section of the AveXis website, www.AveXis.com.  The webcast will be archived on the company’s website until its next quarterly earnings call, and will be available for telephonic replay for 14 days following the call by dialing (855) 859-2056 (Domestic) or (404) 537-3406 (International), conference ID 84652584. About SMA
SMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. The incidence of SMA is approximately one in 10,000 live births. The most severe form of SMA is Type 1, a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, which results in mortality or the need for permanent ventilation support before the age of two for greater than 90 percent of patients. SMA Type 1 is the leading genetic cause of infant mortality. About AVXS-101
AVXS-101 is a proprietary gene therapy candidate of a one-time treatment for SMA Type 1 and is currently in development for SMA. AVXS-101 is designed to address the monogenic root cause of SMA and prevent further muscle degeneration by addressing the defective and/or loss of the primary SMN1 gene. AVXS-101 also targets motor neurons providing rapid onset of effect and crosses the blood brain barrier allowing an IV dosing route and effective targeting of both central and systemic features. About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is in an ongoing Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.avexis.com.  

Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
[email protected]

Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
[email protected]

Read more...
AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting

-- Key preclinical and clinical data of AVXS-101 in SMA to be presented --

CHICAGO, March 02, 2017 (GLOBE NEWSWIRE) -- AveXis, Inc. (NASDAQ:AVXS), a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases, today announced results from the Phase 1 trial of AVXS-101, AveXis’ proprietary gene therapy candidate for the treatment of spinal muscular atrophy (SMA) Type 1, will be presented at the 2017 Annual Meeting of the American Academy of Neurology (AAN) taking place April 22-28 in Boston.
“AVXS‐101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Event-free Survival and Achievement of Developmental Milestones” will be presented by Jerry Mendell, MD, principal investigator in the trial and Curran-Peters Chair of Pediatric Research, Professor of Pediatrics and Neurology at the Research Institute at Nationwide Children’s Hospital and The Ohio State University, Columbus, Ohio, during the Clinical Trial Plenary Session at 10:30 a.m. EDT on April 25, and during the “Best of” Session for Neuromuscular Disease Therapeutics at 8:16 a.m. EDT on April 26. "We are eager to present these data from the first ever clinical trial of gene therapy in spinal muscular atrophy," said Sukumar Nagendran, MD, Chief Medical Officer, AveXis. "AveXis is dedicated to continued research in spinal muscular atrophy, the most common genetic cause of infant mortality, and we look forward to presenting this and other important SMA research at the AAN Annual Meeting." A total of five preclinical and clinical abstracts will be presented during the meeting, underscoring the company’s leadership in pioneering gene therapy to treat life-threatening neurological diseases. In addition to the presentations highlighted above, these include: “AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Experience with Preexisting Anti-AAV9 Antibody in the SMA1 Population;” oral presentation on April 24 at 1:00 p.m. during S13: Motor Neuron Diseases: Biomarkers, Outcome Measures and Therapeutics.“AVXS-101 Phase 1 Gene Therapy Clinical Trial in SMA Type 1: Correlation between CHOP-INTEND and Motor Milestone Achievements;” oral presentation on April 24 at 1:12 p.m. during S13: Motor Neuron Diseases: Biomarkers, Outcome Measures and Therapeutics.“CSF Delivery of AAV9-mediated Gene Therapy for SMA, a Lethal Neuromuscular Disease in Children: A Dose-response Study in Mice and Nonhuman Primates;” poster presentation on April 25 at 5:30 – 7:00 p.m. All abstracts can be accessed through the AAN website at www.aan.com. About SMA
SMA is a severe neuromuscular disease characterized by the loss of motor neurons leading to progressive muscle weakness and paralysis. SMA is caused by a genetic defect in the SMN1 gene that codes SMN, a protein necessary for survival of motor neurons. The incidence of SMA is approximately one in 10,000 live births. The most severe form of SMA is Type 1, a lethal genetic disorder characterized by motor neuron loss and associated muscle deterioration, which results in mortality or the need for permanent ventilation support before the age of two for greater than 90 percent of patients. SMA Type 1 is the leading genetic cause of infant mortality. About AVXS-101
AVXS-101 is a proprietary gene therapy candidate of a one-time treatment for SMA Type 1 and is currently in development for SMA. AVXS-101 is designed to address the monogenic root cause of SMA and prevent further muscle degeneration by addressing the defective and/or loss of the primary SMN1 gene. AVXS-101 also targets motor neurons providing rapid onset of effect, and crosses the blood brain barrier allowing an IV dosing route and effective targeting of both central and systemic features. About AveXis, Inc.
AveXis is a clinical-stage gene therapy company developing treatments for patients suffering from rare and life-threatening neurological genetic diseases. The company’s initial proprietary gene therapy candidate, AVXS-101, is being evaluated in a Phase 1 clinical trial for the treatment of SMA Type 1. For additional information, please visit www.avexis.com.
Media Inquiries:
Lauren Barbiero
W2O Group
646-564-2156
[email protected]

Investor Inquiries:
Jim Goff
AveXis, Inc.
650-862-4134
[email protected]

Read more...

Ratios

vs
industry
vs
history
PB Ratio 8.63
AVXS's PB Ratio is ranked lower than
81% of the 844 Companies
in the Global Biotechnology industry.

( Industry Median: 3.75 vs. AVXS: 8.63 )
Ranked among companies with meaningful PB Ratio only.
AVXS' s PB Ratio Range Over the Past 10 Years
Min: 0  Med: 0 Max: 9.29
Current: 8.63
0
9.29
EV-to-EBIT -18.50
AVXS's EV-to-EBIT is ranked lower than
99.99% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: 22.87 vs. AVXS: -18.50 )
Ranked among companies with meaningful EV-to-EBIT only.
AVXS' s EV-to-EBIT Range Over the Past 10 Years
Min: -29.43  Med: 0 Max: 0
Current: -18.5
-29.43
0
EV-to-EBITDA -18.55
AVXS's EV-to-EBITDA is ranked lower than
99.99% of the 466 Companies
in the Global Biotechnology industry.

( Industry Median: 17.12 vs. AVXS: -18.55 )
Ranked among companies with meaningful EV-to-EBITDA only.
AVXS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -29.44  Med: 0 Max: 0
Current: -18.55
-29.44
0
Current Ratio 8.49
AVXS's Current Ratio is ranked higher than
79% of the 921 Companies
in the Global Biotechnology industry.

( Industry Median: 4.05 vs. AVXS: 8.49 )
Ranked among companies with meaningful Current Ratio only.
AVXS' s Current Ratio Range Over the Past 10 Years
Min: 0.62  Med: 10.37 Max: 15.48
Current: 8.49
0.62
15.48
Quick Ratio 8.49
AVXS's Quick Ratio is ranked higher than
80% of the 920 Companies
in the Global Biotechnology industry.

( Industry Median: 3.77 vs. AVXS: 8.49 )
Ranked among companies with meaningful Quick Ratio only.
AVXS' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 10.37 Max: 15.48
Current: 8.49
0.62
15.48

Buy Back

vs
industry
vs
history

Valuation & Return

vs
industry
vs
history
Price-to-Net-Cash 10.71
AVXS's Price-to-Net-Cash is ranked lower than
65% of the 514 Companies
in the Global Biotechnology industry.

( Industry Median: 6.54 vs. AVXS: 10.71 )
Ranked among companies with meaningful Price-to-Net-Cash only.
AVXS' s Price-to-Net-Cash Range Over the Past 10 Years
Min: 4.52  Med: 6.12 Max: 11.79
Current: 10.71
4.52
11.79
Price-to-Net-Current-Asset-Value 10.29
AVXS's Price-to-Net-Current-Asset-Value is ranked lower than
67% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 6.07 vs. AVXS: 10.29 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
AVXS' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 4.47  Med: 5.99 Max: 11.33
Current: 10.29
4.47
11.33
Price-to-Tangible-Book 8.64
AVXS's Price-to-Tangible-Book is ranked lower than
74% of the 769 Companies
in the Global Biotechnology industry.

( Industry Median: 4.58 vs. AVXS: 8.64 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
AVXS' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 4.26  Med: 5.37 Max: 9.51
Current: 8.64
4.26
9.51
Earnings Yield (Greenblatt) % -5.42
AVXS's Earnings Yield (Greenblatt) % is ranked higher than
56% of the 1272 Companies
in the Global Biotechnology industry.

( Industry Median: -6.37 vs. AVXS: -5.42 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
AVXS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -1680.15  Med: 0 Max: 0
Current: -5.42
-1680.15
0

More Statistics

EPS (TTM) $ -3.54
Short Percentage of Float23.11%
52-Week Range $31.55 - 85.98
Shares Outstanding (Mil)27.79

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $)
EPS ($) -4.67 -5.56 -4.48
EPS without NRI ($) -4.67 -5.56 -4.48
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for AVXS

Headlines

Articles On GuruFocus.com
AveXis Reports First Quarter 2017 Financial and Operating Results May 11 2017 
AveXis to Report First Quarter 2017 Financial and Operating Results May 04 2017 
AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the Am Apr 25 2017 
AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual Me Apr 18 2017 
AveXis to Report Topline Phase 1 Trial Results in SMA Type 1 and Fourth Quarter and Full Year 2016 F Mar 09 2017 
AveXis to Present Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at AAN Annual Meeting Mar 02 2017 

More From Other Websites
What Falling Estimates & Price Mean for AveXis, Inc. (AVXS) May 18 2017
AveXis reports 1Q loss May 11 2017
AveXis Reports First Quarter 2017 Financial and Operating Results May 11 2017
AveXis to Report First Quarter 2017 Financial and Operating Results May 04 2017
High-Stakes Meeting Between Avexis and FDA Will Set the Course for Gene Therapy and Dying Kids Apr 26 2017
AveXis Presents Results from Phase 1 Trial of AVXS-101 in SMA Type 1 at the Annual Meeting of the... Apr 25 2017
AveXis to Host Webcast of Preclinical and Clinical Studies of AVXS-101 as Presented at the Annual... Apr 18 2017
Which Biotechs Are Buyable As Sector Recovers In 2017? Mar 30 2017
Cytokinetics SMA Drug Did Well in Early Study Mar 22 2017
Billionaires' Best Healthcare Stock Picks of 2017 (So Far) Mar 21 2017
AveXis, Inc. (AVXS) Looks Good: Stock Moves 15.4% Higher Mar 20 2017
AveXis Inc Stock Is Spiking Again Today -- Here's Why Mar 17 2017
AveXis, Esperion and Amgen Among Biotech Movers Mar 17 2017
AveXis Reports Positive Data for SMA Gene Therapy Mar 17 2017
AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients Mar 17 2017
Edited Transcript of AVXS earnings conference call or presentation 16-Mar-17 8:30pm GMT Mar 17 2017
Futures Steady: 2 'A' Stocks Set To Soar, 1 Mule Ready To Kick Mar 16 2017
After-hours buzz: ADBE, AVXS, GOOS & more Mar 16 2017
AveXis Reports Topline Results from Phase 1 Trial of AVXS-101 in SMA Type 1 and Fourth Quarter and... Mar 16 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat